Published in Biochemistry on October 03, 2006
Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol (2009) 5.27
Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nat Med (2015) 2.83
Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol (2008) 2.27
N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol (2011) 2.18
Minireview: protein arginine methylation of nonhistone proteins in transcriptional regulation. Mol Endocrinol (2009) 1.95
Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem (2008) 1.93
Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res (2014) 1.93
Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel (2009) 1.83
Citrullination regulates pluripotency and histone H1 binding to chromatin. Nature (2014) 1.81
Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta (2008) 1.69
Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry (2010) 1.66
Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest (2013) 1.64
Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol (2011) 1.61
Protein arginine deiminase 4: evidence for a reverse protonation mechanism. Biochemistry (2007) 1.45
Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J Biol Chem (2012) 1.45
Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol (2015) 1.41
Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation. Proc Natl Acad Sci U S A (2012) 1.35
Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells. PLoS Genet (2011) 1.33
Activation of PAD4 in NET formation. Front Immunol (2012) 1.30
Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors. ACS Chem Biol (2011) 1.25
Activity-based protein profiling reagents for protein arginine deiminase 4 (PAD4): synthesis and in vitro evaluation of a fluorescently labeled probe. J Am Chem Soc (2006) 1.24
Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell Mol Life Sci (2010) 1.21
Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis. Biochim Biophys Acta (2013) 1.20
The protein arginine deiminases: Structure, function, inhibition, and disease. Biopolymers (2013) 1.18
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer (2012) 1.18
A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem Commun (Camb) (2010) 1.13
An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4 (PAD4). Tetrahedron Lett (2008) 1.13
Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation. Chembiochem (2010) 1.13
Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther (2009) 1.12
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem (2007) 1.11
Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. Biochem Res Int (2012) 1.08
Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther (2014) 1.07
Citrullination of histone H3 interferes with HP1-mediated transcriptional repression. PLoS Genet (2012) 1.04
Bacterial and human peptidylarginine deiminases: targets for inhibiting the autoimmune response in rheumatoid arthritis? Arthritis Res Ther (2010) 1.03
Pluripotency: citrullination unravels stem cells. Nat Chem Biol (2014) 1.01
Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo. Nanomedicine (Lond) (2012) 1.00
Active site cysteine is protonated in the PAD4 Michaelis complex: evidence from Born-Oppenheimer ab initio QM/MM molecular dynamics simulations. J Phys Chem B (2009) 1.00
Chemical biology of protein arginine modifications in epigenetic regulation. Chem Rev (2015) 0.99
Discovery of halopyridines as quiescent affinity labels: inactivation of dimethylarginine dimethylaminohydrolase. J Am Chem Soc (2011) 0.97
Born-Oppenheimer ab initio QM/MM molecular dynamics simulations of the hydrolysis reaction catalyzed by protein arginine deiminase 4. J Phys Chem B (2009) 0.97
Mechanistic similarity and diversity among the guanidine-modifying members of the pentein superfamily. Biochim Biophys Acta (2010) 0.95
Autodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity. Biochemistry (2011) 0.95
Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11. Br J Pharmacol (2014) 0.94
Seeing citrulline: development of a phenylglyoxal-based probe to visualize protein citrullination. J Am Chem Soc (2012) 0.93
Use of Fluorinated Functionality in Enzyme Inhibitor Development: Mechanistic and Analytical Advantages. J Fluor Chem (2008) 0.92
The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS One (2013) 0.91
A chloroacetamidine-based inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation. Chembiochem (2010) 0.91
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
Design, synthesis, and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors. J Med Chem (2015) 0.90
Classical ROS-dependent and early/rapid ROS-independent release of Neutrophil Extracellular Traps triggered by Leishmania parasites. Sci Rep (2015) 0.90
Chemical and biological methods to detect post-translational modifications of arginine. Biopolymers (2014) 0.88
Activity-based protein profiling of protein arginine methyltransferase 1. ACS Chem Biol (2011) 0.88
Characterization and inactivation of an agmatine deiminase from Helicobacter pylori. Bioorg Chem (2009) 0.88
A combinatorial approach to characterize the substrate specificity of protein arginine methyltransferase 1. Mol Biosyst (2010) 0.86
D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy. ACS Med Chem Lett (2012) 0.86
Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4. ACS Chem Biol (2011) 0.86
Promiscuous partitioning of a covalent intermediate common in the pentein superfamily. Chem Biol (2008) 0.85
Peptidyl arginine deiminase-4 activation exacerbates kidney ischemia-reperfusion injury. Am J Physiol Renal Physiol (2014) 0.85
Site-specific and regiospecific installation of methylarginine analogues into recombinant histones and insights into effector protein binding. J Am Chem Soc (2013) 0.85
PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation. Nat Commun (2014) 0.85
Peptidylarginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates. J Neurochem (2014) 0.84
Molecular targeting of protein arginine deiminases to suppress colitis and prevent colon cancer. Oncotarget (2015) 0.83
Mechanistic studies of agmatine deiminase from multiple bacterial species. Biochemistry (2010) 0.82
Extracellular traps and macrophages: new roles for the versatile phagocyte. J Leukoc Biol (2015) 0.81
Protein Arginine Methylation and Citrullination in Epigenetic Regulation. ACS Chem Biol (2015) 0.81
A FluoPol-ABPP PAD2 high-throughput screen identifies the first calcium site inhibitor targeting the PADs. ACS Chem Biol (2014) 0.81
A novel role for protein arginine deiminase 4 in pluripotency: the emerging role of citrullinated histone H1 in cellular programming. Bioessays (2014) 0.80
Structure-informed design of an enzymatically inactive vaccine component for group A Streptococcus. MBio (2013) 0.80
Decreased severity of experimental autoimmune arthritis in peptidylarginine deiminase type 4 knockout mice. BMC Musculoskelet Disord (2016) 0.80
Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening. BMC Bioinformatics (2012) 0.79
Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation. Curr Drug Targets (2015) 0.79
Chemical Proteomic Platform To Identify Citrullinated Proteins. ACS Chem Biol (2015) 0.79
Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method. J Am Chem Soc (2015) 0.78
Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation. Bioorg Med Chem (2014) 0.77
Iron-chelating agent desferrioxamine stimulates formation of neutrophil extracellular traps (NETs) in human blood-derived neutrophils. Biosci Rep (2016) 0.77
Inhibitors of Serine Proteases in Regulating the Production and Function of Neutrophil Extracellular Traps. Front Immunol (2016) 0.77
Inhibiting protein arginine deiminases has antioxidant consequences. J Pharmacol Exp Ther (2015) 0.77
Peptidylarginine Deiminase Inhibitor Suppresses Neutrophil Extracellular Trap Formation and MPO-ANCA Production. Front Immunol (2016) 0.77
Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev (2017) 0.76
PADI4 haplotypes in association with RA Mexican patients, a new prospect for antigen modulation. Clin Dev Immunol (2013) 0.76
Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds. Oncotarget (2016) 0.75
Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis. Clin Exp Immunol (2017) 0.75
A novel PAD4/SOX4/PU.1 signaling pathway is involved in the committed differentiation of acute promyelocytic leukemia cells into granulocytic cells. Oncotarget (2016) 0.75
Cl-Amidine Prevents Histone 3 Citrullination and Neutrophil Extracellular Trap Formation, and Improves Survival in a Murine Sepsis Model. J Innate Immun (2016) 0.75
Molecular Interplay between the Dimer Interface and the Substrate-Binding Site of Human Peptidylarginine Deiminase 4. Sci Rep (2017) 0.75
Cellular Activity of New Small Molecule Protein Arginine Deiminase 3 (PAD3) Inhibitors. ACS Med Chem Lett (2016) 0.75
Interrogation of the Active Sites of Protein Arginine Deiminases (PAD1, -2, and -4) Using Designer Probes. ACS Med Chem Lett (2013) 0.75
Fluorescence-based monitoring of PAD4 activity via a pro-fluorescence substrate analog. J Vis Exp (2014) 0.75
Transcriptional firing helps to drive NETosis. Sci Rep (2017) 0.75
Neutrophil Extracellular Traps Enhance Early Inflammatory Response in Sendai Virus-Induced Asthma Phenotype. Front Immunol (2016) 0.75
Citrullination/Methylation Crosstalk on Histone H3 Regulates ER-Target Gene Transcription. ACS Chem Biol (2017) 0.75
Identification of Padi2 as a novel angiogenesis-regulating gene by genome association studies in mice. PLoS Genet (2017) 0.75
Lowering relative humidity level increases epidermal protein deimination and drives human filaggrin breakdown. J Dermatol Sci (2017) 0.75
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A (1991) 119.63
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum (2000) 8.64
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet (2003) 7.04
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest (1998) 6.92
Human PAD4 regulates histone arginine methylation levels via demethylimination. Science (2004) 5.46
Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal (2005) 5.37
Histone deimination antagonizes arginine methylation. Cell (2004) 5.19
PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays (2003) 5.04
Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol (2003) 4.64
The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol (2001) 3.92
The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol (1999) 3.22
Structural basis for Ca(2+)-induced activation of human PAD4. Nat Struct Mol Biol (2004) 2.74
Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination. Proc Natl Acad Sci U S A (2005) 2.40
Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis. Biochemistry (2005) 2.21
Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther (2005) 2.03
Molecular characterization of peptidylarginine deiminase in HL-60 cells induced by retinoic acid and 1alpha,25-dihydroxyvitamin D(3). J Biol Chem (1999) 1.93
A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc (2006) 1.85
In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol (2000) 1.77
A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis Rheum (2006) 1.68
Deimination of arginine residues in nucleophosmin/B23 and histones in HL-60 granulocytes. Biochem Biophys Res Commun (2002) 1.66
Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine: dimethylargininase and peptidylarginine deiminase. Biochemistry (2005) 1.65
Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun (1998) 1.42
Overexpression of peptidylarginine deiminase IV features in apoptosis of haematopoietic cells. Apoptosis (2006) 1.36
Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum (2002) 1.26
Deimination of histone H2A and H4 at arginine 3 in HL-60 granulocytes. Biochemistry (2005) 1.22
Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis. Ann Rheum Dis (2001) 1.15
Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum (2002) 1.12
A novel microtubule independent effect of paclitaxel: the inhibition of peptidylarginine deiminase from bovine brain. Biochim Biophys Acta (1998) 1.06
Crystallization and preliminary X-ray crystallographic analysis of human peptidylarginine deiminase V. Acta Crystallogr D Biol Crystallogr (2003) 0.96
Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 position. J Med Chem (1990) 0.93
Unlocking the "PAD" lock on rheumatoid arthritis. Ann Rheum Dis (2004) 0.83
Human PAD4 regulates histone arginine methylation levels via demethylimination. Science (2004) 5.46
The ankyrin repeats of G9a and GLP histone methyltransferases are mono- and dimethyllysine binding modules. Nat Struct Mol Biol (2008) 3.20
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature (2008) 2.83
Structural basis for Ca(2+)-induced activation of human PAD4. Nat Struct Mol Biol (2004) 2.74
Role of protein methylation in regulation of transcription. Endocr Rev (2004) 2.57
Synergy among nuclear receptor coactivators: selective requirement for protein methyltransferase and acetyltransferase activities. Mol Cell Biol (2002) 2.51
Crystal structure of the human centromeric nucleosome containing CENP-A. Nature (2011) 2.42
Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination. Proc Natl Acad Sci U S A (2005) 2.40
Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol (2008) 2.27
Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis. Biochemistry (2005) 2.21
N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol (2011) 2.18
Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg (2012) 2.01
Lipopolysaccharide-induced methylation of HuR, an mRNA-stabilizing protein, by CARM1. Coactivator-associated arginine methyltransferase. J Biol Chem (2002) 2.01
Histone H3 lysine 9 methyltransferase G9a is a transcriptional coactivator for nuclear receptors. J Biol Chem (2006) 1.96
Minireview: protein arginine methylation of nonhistone proteins in transcriptional regulation. Mol Endocrinol (2009) 1.95
Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. J Biol Chem (2008) 1.93
Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res (2014) 1.93
Activation of nuclear receptor coactivator PGC-1alpha by arginine methylation. Genes Dev (2005) 1.92
A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J Am Chem Soc (2006) 1.85
Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel (2009) 1.83
Clinical outcomes of 3 fusion methods through the posterior approach in the lumbar spine. Spine (Phila Pa 1976) (2006) 1.78
CoCoA, a nuclear receptor coactivator which acts through an N-terminal activation domain of p160 coactivators. Mol Cell (2003) 1.75
Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-catenin with two different classes of DNA-binding transcriptional activators. J Biol Chem (2002) 1.71
Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry (2010) 1.66
CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes. Mol Cell (2008) 1.66
The roles of protein-protein interactions and protein methylation in transcriptional activation by nuclear receptors and their coactivators. J Steroid Biochem Mol Biol (2003) 1.65
Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest (2013) 1.64
The coactivator-associated arginine methyltransferase is necessary for muscle differentiation: CARM1 coactivates myocyte enhancer factor-2. J Biol Chem (2001) 1.62
Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol (2011) 1.61
Protein arginine methyltransferase 1: positively charged residues in substrate peptides distal to the site of methylation are important for substrate binding and catalysis. Biochemistry (2007) 1.55
Epithelial Na+ channel proteins are mechanotransducers of myogenic constriction in rat posterior cerebral arteries. Exp Physiol (2011) 1.54
Health-related quality of life (HRQoL): the impact of medical and demographic variables upon pediatric recipients of hematopoietic stem cell transplantation. Pediatr Blood Cancer (2011) 1.52
Hematogones are markedly reduced in pediatric acquired aplastic anemia: multiparametric flow cytometric analysis. Leuk Lymphoma (2009) 1.51
Developmentally essential protein flightless I is a nuclear receptor coactivator with actin binding activity. Mol Cell Biol (2004) 1.49
Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4. Proc Natl Acad Sci U S A (2006) 1.48
Structural basis for novel interactions between human translesion synthesis polymerases and proliferating cell nuclear antigen. J Biol Chem (2009) 1.48
Structural basis for distinct roles of Lys63- and Lys48-linked polyubiquitin chains. Genes Cells (2004) 1.45
Protein arginine deiminase 4: evidence for a reverse protonation mechanism. Biochemistry (2007) 1.45
In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. J Am Chem Soc (2008) 1.42
Crystal structure of human REV7 in complex with a human REV3 fragment and structural implication of the interaction between DNA polymerase zeta and REV1. J Biol Chem (2010) 1.40
Report of the wwPDB Small-Angle Scattering Task Force: data requirements for biomolecular modeling and the PDB. Structure (2013) 1.39
Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular chromatin traps. Arthritis Rheum (2011) 1.38
Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37
Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation. Proc Natl Acad Sci U S A (2012) 1.35
Requirement for multiple domains of the protein arginine methyltransferase CARM1 in its transcriptional coactivator function. J Biol Chem (2002) 1.33
Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells. PLoS Genet (2011) 1.33
Kinetic mechanism of protein arginine methyltransferase 1. Biochemistry (2008) 1.32
VDUP1 is required for the development of natural killer cells. Immunity (2005) 1.31
Activation of PAD4 in NET formation. Front Immunol (2012) 1.30
Recognition of enhancer element-specific histone methylation by TIP60 in transcriptional activation. Nat Struct Mol Biol (2011) 1.29
Requirement of cell cycle and apoptosis regulator 1 for target gene activation by Wnt and beta-catenin and for anchorage-independent growth of human colon carcinoma cells. J Biol Chem (2009) 1.26
Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors. ACS Chem Biol (2011) 1.25
Characterization of neural cell types expressing peroxiredoxins in mouse brain. Neurosci Lett (2005) 1.25
Activity-based protein profiling reagents for protein arginine deiminase 4 (PAD4): synthesis and in vitro evaluation of a fluorescently labeled probe. J Am Chem Soc (2006) 1.24
Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant (2011) 1.24
Recognition of modification status on a histone H3 tail by linked histone reader modules of the epigenetic regulator UHRF1. Proc Natl Acad Sci U S A (2012) 1.22
Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell Mol Life Sci (2010) 1.21
Structural basis for substrate recognition and dissociation by human transportin 1. Mol Cell (2007) 1.21
Distinguishing crystal-like amyloid fibrils and glass-like amorphous aggregates from their kinetics of formation. Proc Natl Acad Sci U S A (2012) 1.19
The protein arginine deiminases: Structure, function, inhibition, and disease. Biopolymers (2013) 1.18
The crystal structure of the novel calcium-binding protein AtCBL2 from Arabidopsis thaliana. J Biol Chem (2003) 1.18
Synergistic effects of coactivators GRIP1 and beta-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways. J Biol Chem (2003) 1.18
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer (2012) 1.18
G9a functions as a molecular scaffold for assembly of transcriptional coactivators on a subset of glucocorticoid receptor target genes. Proc Natl Acad Sci U S A (2012) 1.17
A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem Commun (Camb) (2010) 1.13
An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4 (PAD4). Tetrahedron Lett (2008) 1.13
GAC63, a GRIP1-dependent nuclear receptor coactivator. Mol Cell Biol (2005) 1.13
Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation. Chembiochem (2010) 1.13
Transcriptional intermediary factor 1alpha mediates physical interaction and functional synergy between the coactivator-associated arginine methyltransferase 1 and glucocorticoid receptor-interacting protein 1 nuclear receptor coactivators. Mol Endocrinol (2005) 1.13
The protein acetyltransferase ARD1: a novel cancer drug target? Curr Cancer Drug Targets (2008) 1.13
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res (2012) 1.13
Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant (2012) 1.12
Interplay of Fli-I and FLAP1 for regulation of beta-catenin dependent transcription. Nucleic Acids Res (2006) 1.12
Protein deiminases: new players in the developmentally regulated loss of neural regenerative ability. Dev Biol (2011) 1.12
Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer. Endocrinology (2008) 1.12
Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem (2007) 1.11
Detection and identification of Mycobacterium tuberculosis in joint biopsy specimens by rpoB PCR cloning and sequencing. J Clin Microbiol (2005) 1.10
A distinct mechanism for coactivator versus corepressor function by histone methyltransferase G9a in transcriptional regulation. J Biol Chem (2011) 1.09
Reciprocal roles of DBC1 and SIRT1 in regulating estrogen receptor α activity and co-activator synergy. Nucleic Acids Res (2011) 1.09
Hepatitis delta virus antigen is methylated at arginine residues, and methylation regulates subcellular localization and RNA replication. J Virol (2004) 1.08
Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. Biochem Res Int (2012) 1.08
Role of the coiled-coil coactivator (CoCoA) in aryl hydrocarbon receptor-mediated transcription. J Biol Chem (2004) 1.08
Gene-specific patterns of coregulator requirements by estrogen receptor-α in breast cancer cells. Mol Endocrinol (2012) 1.07